Advertisement

Hepatology International

, Volume 12, Issue 5, pp 465–473 | Cite as

Tolerable and curable treatment in HIV/HCV co-infected patients using anti-HCV direct antiviral agents: a real-world observation in China

  • Yuanyuan Li
  • Linghua Li
  • Jun Liu
  • Da-Wei Zhang
  • Fang Zhao
  • Li Wang
  • Aizezi. Mahemure
  • Ronghui Xie
  • Suyun Lei
  • Weiping Cai
  • Xicheng Wang
  • Zhanjun Shu
  • Xiejie Chen
  • Hui WangEmail author
  • Fu-Sheng WangEmail author
Original Article

Abstract

Objective

No brand direct-acting antiviral agents (DAAs) are available for treatment of HIV-1/HCV co-infected patients in China. This study aimed to observe the therapeutic efficacy and safety of generic DAAs for affected Chinese patients.

Design

Real-world setting to elucidate whether DAAs were tolerated and effective in HIV-1/HCV co-infected patients.

Methods

176 HIV-1/HCV co-infected patients received anti-HCV DAA treatment together with ART regimens for HIV infection. Among the 176 patients, 99 patients were treated with SOF + DCV ± RBV, 60 patients were treated with SOF + LDV ± RBV, and 17 patients received SOF + RBV ± Peg-IFN regimens, for 12 or 24 weeks, respectively. The primary endpoint was undetectable HCV RNA 12 weeks after therapy was completed (SVR12). Data pertaining to safety and adverse events were analyzed.

Results

151/176 HIV-1/HCV co-infected patients finished the treatment and 12-week follow-up. SVR12 for the patients treated with regimens of SOF + DCV, SOF + DCV+RBV, SOF + Peg-IFN+RBV, SOF + RBV, SOF + LDV, and SOF + LDV+RBV for 12 or 24 weeks was 100% (75/75), 100% (11/11), 100% (14/14), 100% (2/2), 95.2% (40/42), and 100% (7/7), respectively. HIV-1/HCV co-infected patients with liver cirrhosis achieved well SRV12. Notably, there was no significant difference in adverse effects among patients with different baseline CD4+ T-cell count in those who received DAA regimens with or without Peg-IFN and RBV.

Conclusion

We showed generic SOF + DCV and SOF + LDV regimens were well tolerated and with high efficiency. Patient’s baseline CD4+ T-cell count did not exhibit significant difference in adverse effects.

Keywords

Generic DAAs SOF Hepatitis C HIV-1 patients Co-infected 

Notes

Authors’ contributions

Yuanyuan Li, Linghua Li, and Jun Liu contributed equally as co-first authors. Fu-Sheng Wang contributed to the design of this study. All authors contributed to data collection, the interpretation of data, the drafting, and revision of this manuscript. The final version of this manuscript was approved by all authors.

Financial support

This study was supported by The National Natural Science Foundation of China (No. 81601731).

Compliance with ethical standards

Conflict of interest

Yuanyuan Li, Linghua Li, Jun Liu, Da-Wei Zhang, Fang Zhao, Li Wang, Aizezi Mahemure, Ronghui Xie, Suyun Lei, Weiping Cai, Xicheng Wang, Zhanjun Shu, Xiejie Chen, Hui Wang, and Fu-Sheng Wang declared that there were no conflicts regarding funding or interest with this manuscript.

Ethical approval

This study protocol had been approved by the ethical committee of the Beijing 302 hospital and other institutions involved.

References

  1. 1.
    Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62(3):932–954.  https://doi.org/10.1002/hep.27950 CrossRefGoogle Scholar
  2. 2.
    Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192(6):992–1002.  https://doi.org/10.1086/432762 CrossRefPubMedGoogle Scholar
  3. 3.
    Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009;49(10):1605–1615.  https://doi.org/10.1086/644771 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Data Collection on Adverse Events of Anti HIVdSG, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A: D Study. AIDS 2010;24(10):1537–1548.  https://doi.org/10.1097/qad.0b013e32833a0918 CrossRefGoogle Scholar
  5. 5.
    Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356(9244):1800–1805CrossRefPubMedGoogle Scholar
  6. 6.
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351(5):438–450.  https://doi.org/10.1056/NEJMoa040842 CrossRefPubMedGoogle Scholar
  7. 7.
    Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351(5):451–459.  https://doi.org/10.1056/NEJMoa032653 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Zhu SS, Zeng QL, Dong Y, Xu ZQ, Wang LM, Chen DW, et al. Interferon-alpha plus ribavirin yields 98% sustained virologic response in children aged 1–5 years with iatrogenic chronic hepatitis C. Hepatol Int 2015;9(4):578–585.  https://doi.org/10.1007/s12072-015-9671-8 CrossRefPubMedGoogle Scholar
  9. 9.
    Shi J, Li Y, Chang W, Zhang X, Wang FS. Current progress in host innate and adaptive immunity against hepatitis C virus infection. Hepatol Int 2017;11(4):374–383.  https://doi.org/10.1007/s12072-017-9805-2 CrossRefPubMedGoogle Scholar
  10. 10.
    Wyles DL, Sulkowski MS, Dieterich D. Management of hepatitis C/HIV Coinfection in the era of highly effective hepatitis C virus direct-acting antiviral therapy. Clin Infect Dis 2016;63(Suppl 1):S3–S11.  https://doi.org/10.1093/cid/ciw219 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373(8):714–725.  https://doi.org/10.1056/NEJMoa1503153 CrossRefPubMedGoogle Scholar
  12. 12.
    Luetkemeyer AF, McDonald C, Ramgopal M, Noviello S, Bhore R, Ackerman P. 12 weeks of daclatasvir in combination with sofosbuvir for HIV–HCV coinfection (ALLY-2 study): efficacy and safety by HIV combination antiretroviral regimens. Clin Infect Dis 2016;62(12):1489–1496.  https://doi.org/10.1093/cid/ciw163 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015;373(8):705–713.  https://doi.org/10.1056/NEJMoa1501315 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015;313(12):1232–1239.  https://doi.org/10.1001/jama.2015.1373 CrossRefPubMedGoogle Scholar
  15. 15.
    Zhang F, Zhu H, Wu Y, Dou Z, Zhang Y, Kleinman N, et al. HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010–2012: a retrospective observational cohort study. Lancet Infect Dis 2014;14(11):1065–1072.  https://doi.org/10.1016/S1473-3099(14)70946-6 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Zeng QL, Xu GH, Zhang JY, Li W, Zhang DW, Li ZQ, et al. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study. J Hepatol 2017;66(6):1123–1129.  https://doi.org/10.1016/j.jhep.2017.01.025 CrossRefPubMedGoogle Scholar
  17. 17.
    European Association for the Study of the Liver. Electronic address eee. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017;66(1):153–194.  https://doi.org/10.1016/j.jhep.2016.09.001 CrossRefGoogle Scholar
  18. 18.
    Hezode C, Bronowicki JP. Ideal oral combinations to eradicate HCV: the role of ribavirin. J Hepatol 2016;64(1):215–225.  https://doi.org/10.1016/j.jhep.2015.09.009 CrossRefPubMedGoogle Scholar
  19. 19.
    Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;64(6):1224–1231.  https://doi.org/10.1016/j.jhep.2016.01.029 CrossRefPubMedGoogle Scholar
  20. 20.
    Simmons B, Saleem J, Hill A, Riley RD, Cooke GS. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis 2016;62(6):683–694.  https://doi.org/10.1093/cid/civ948 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. AIDS 2015;29(17):2335–2345.  https://doi.org/10.1097/QAD.0000000000000834 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    El-Sherif O, Khoo S, Solas C. Key drug-drug interactions with direct-acting antiviral in HIV–HCV coinfection. Curr opin HIV AIDS 2015;10(5):348–354.  https://doi.org/10.1097/COH.0000000000000185 CrossRefPubMedGoogle Scholar
  23. 23.
    Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Henry L, Hunt S. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. J Viral Hepatitis 2016;23(11):857–865.  https://doi.org/10.1111/jvh.12554 CrossRefGoogle Scholar
  24. 24.
    Younossi ZM, Stepanova M, Sulkowski M, Wyles D, Kottilil S, Hunt S. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: the ASTRAL-5 study. Liver Int 2017;37(12):1796–1804.  https://doi.org/10.1111/liv.13462 CrossRefPubMedGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2018

Authors and Affiliations

  • Yuanyuan Li
    • 1
  • Linghua Li
    • 2
  • Jun Liu
    • 3
  • Da-Wei Zhang
    • 1
  • Fang Zhao
    • 4
  • Li Wang
    • 5
  • Aizezi. Mahemure
    • 6
  • Ronghui Xie
    • 5
  • Suyun Lei
    • 5
  • Weiping Cai
    • 2
  • Xicheng Wang
    • 5
  • Zhanjun Shu
    • 6
  • Xiejie Chen
    • 2
  • Hui Wang
    • 4
    Email author
  • Fu-Sheng Wang
    • 1
    Email author
  1. 1.Research and Treatment Center of Infectious DiseasesBeijing 302 HospitalBeijingChina
  2. 2.Department of Infectious DiseasesGuangzhou Eighth People’s HospitalGuangzhouChina
  3. 3.Kunming Third People’s HospitalKunmingChina
  4. 4.Department of Infectious DiseaseShenzhen Third People’s HospitalShenzhenChina
  5. 5.Department of Infectious DiseasesYunnan Provincial Hospital of Infectious DiseasesKunmingChina
  6. 6.Xinjiang Uygur Autonomous Region Infectious Diseases HospitalÜrümqiChina

Personalised recommendations